Celcuity Inc将在FDA实时肿瘤学审查项目下启动Gedatolisib在HR+/HER2-晚期乳腺癌PIK3CA野生型队列中的新药申请提交。
Celcuity Inc将在FDA实时肿瘤学审查项目下启动Gedatolisib在HR+/HER2-晚期乳腺癌PIK3CA野生型队列中的新药申请提交。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.